In our study, we also demonstrated that SRPK1 and SRSF1 were involved in the production of alternative splicing of VEGF-A165b in RCC cells and promoted cancer progression, which is consistent with the anti-angiogenic effect of VEGF-A165b in previous studies [51–53]. Here, SRSF1 is linked to renal cell carcinoma.